ESPR entered into a major partnership agreement with Daichi Sankyo Europe to commercialize bempadoic acid (BA), its oral drug for lowering LDL-C for patients who are on maximum statins, in Europe. The market did not react favorably to the deal likely because Daichi is not a top 3 worldwide cardio company, but we think the deal is a good one for ESPR and further validates the value of BA. You can see more details on our Catalyst Calendar entry at https://www.ampbioresearch.com/member-catalyst-calendar.
top of page
bottom of page